• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by MDxHealth SA

    7/3/25 4:48:27 PM ET
    $MDXH
    Medical Specialities
    Health Care
    Get the next $MDXH alert in real time by email
    6-K 1 ea0248177-6k_mdxhealth.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2024

     

    Commission File Number 001-40996

     

    MDXHEALTH SA

    (Translation of registrant’s name into English)

     

    CAP Business Center

    Zone Industrielle des Hauts-Sarts

    4040 Herstal, Belgium

    +32 4 257 70 21

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒    Form 40-F ☐

     

     

     

     

    MDXHEALTH SA

     

    On July 3, 2024, the Company announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee, effective July 3, 2025. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May 2025. Additionally, the Company announced that Ron Kalfus has resigned from his position as Chief Financial Officer (“CFO”) to pursue other opportunities. Mr. Kalfus will continue to serve in the role of CFO until his departure on July 30, 2025, at which time the CFO responsibilities at the Company will be assumed on an interim basis by Scott McMahan, Vice President of Finance and Accounting.

     

    On July 3, 2025, the Company issued a press release related to the above, a copy of which is attached hereto as Exhibit 99.1.

     

    Information Incorporated by Reference

     

    This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-268885 and 333-280606) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished; provided, however, the information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

     

    Exhibit No.   Description of Exhibit
    99.1   Press Release, dated July 3, 2025

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      MDXHEALTH SA
         
    Date: July 3, 2025 By: /s/ Michael McGarrity
        Name:  Michael McGarrity
        Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $MDXH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MDXH

    DatePrice TargetRatingAnalyst
    10/31/2024$7.00Buy
    Lake Street
    5/31/2023$7.00Outperform
    TD Cowen
    7/18/2022$18.00Outperform
    Oppenheimer
    More analyst ratings

    $MDXH
    SEC Filings

    See more
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      7/3/25 4:48:27 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      6/6/25 5:12:22 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      5/14/25 4:05:22 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on MDxHealth SA with a new price target

      Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00

      10/31/24 8:59:17 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • TD Cowen initiated coverage on MDxHealth SA with a new price target

      TD Cowen initiated coverage of MDxHealth SA with a rating of Outperform and set a new price target of $7.00

      5/31/23 7:34:28 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Oppenheimer resumed coverage on MDxHealth SA with a new price target

      Oppenheimer resumed coverage of MDxHealth SA with a rating of Outperform and set a new price target of $18.00

      7/18/22 9:23:47 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mvm Partners, Llc bought $4,000,000 worth of shares (1,000,000 units at $4.00)

      4 - MDxHealth SA (0001872529) (Issuer)

      2/28/23 4:22:02 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors

                  Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie

      7/8/24 8:00:00 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Resignation of Board Member

      Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert's resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity, CEO of mdxhealth, commented: "On behalf of the Board of Directors and the employees of mdxhealth, I would like to thank Jan for his suppor

      2/16/24 8:45:00 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Financials

    Live finance-specific insights

    See more
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our perfo

      2/26/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      11/14/24 3:15:43 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MDxHealth SA

      SC 13D/A - MDxHealth SA (0001872529) (Subject)

      10/28/24 2:52:50 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      10/4/24 5:14:19 PM ET
      $MDXH
      Medical Specialities
      Health Care